OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, January 01, 2010

Statins and Breast Cancer in Postmenopausal Women without Hormone Therapy — Anticancer Research



Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG ph 111



Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial

"For currently unknown reasons, administering PLD with carboplatin appears to substantially reduce the incidence of platinum-associated hypersensitivity reactions."

Mutations in Cancer and Therapeutic Resistance: World Without End? -- AACR



Comparison of extended colectomy and limited resection in patients with Lynch syndrome



includes prophylactic (preventative) surgery

Guidelines for the management of ovarian cancer during pregnancy.



"If chemotherapy is indicated, we recommend delaying administration, if possible, until after the delivery or at least after 20 weeks in order to minimize the potential fetal toxicity".

Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer?



Note: It's unfortunate that early stages of ovarian cancers were not included in this study.

Thursday, December 31, 2009

Patient Participation: Current Knowledge and Applicability to Patient Safety — Mayo Clinic Proceedings



Ovarian metastases from breast cancer



"Ovarian disease (cancer) was diagnosed at a median of 5 years after breast cancer. Seventy-five percent of patients were asymptomatic, and advanced-stage pelvic extent or extra-abdominal metastases were observed in 41.5% of patients. The median survival was 3 years..."

Safety Considerations and Potential Interactions of Vitamins: Should Vitamins Be Considered Drugs?



"...A, E, D can cause serious adverse events."

The Optimal Debulking after Neoadjuvant Chemotherapy in Ovarian Cancer: Proposal Based on Interval Look During Upfront Surgery Setting Treatment -- Onda et al. 40 (1): 36 -- Japanese Journal of Clinical Oncology




Under-treatment of cancer pain




Identifying novel autoantibody signatures in ovarian cancer



CONCLUSIONS: Protein microarrays are suitable for autoantibody discovery in ovarian cancer but the signatures are of low frequency.